Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information - Schedule of Consolidated Statements of Operations (Details)

v3.25.1
Segment Information - Schedule of Consolidated Statements of Operations (Details) - Operating Segment [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Salaries and related expenses, other than share-based compensation $ 10,507 $ 8,350
Clinical trials 12,301 8,270
Stock based compensation 1,848 1,059
Depreciation expenses 1,803 871
Goodwill, IPR&D and long-lived assets impairment 8,084
Other segment items [1] 9,980 6,798
Total Operating expenses $ 44,523 $ 25,348
[1] Other segment items include all remaining costs necessary to operate our business, which primarily include external professional services, rent, insurance and other administrative expenses, net of grants received.